Daiichi Sankyo's release explains that American Regent was the market-facing brand of Luitpold Pharmaceuticals (a Daiichi Sankyo U.S. subsidiary), that American Regent and PharmaForce merged into Luitpold, and that the surviving entity was renamed American Regent, Inc. effective January 2019.
American Regent, Inc. and PharmaForce, Inc., subsidiaries of Luitpold Pharmaceuticals, Inc. (Headquarters: New York State, USA; hereafter, Luitpold) are to undergo an absorption-type merger with Luitpold as the surviving company. The name of said surviving company, Luitpold, is to be changed to American Regent, Inc., effective January 2019.
Daiichi Sankyo's release explains that American Regent was the market-facing brand of Luitpold Pharmaceuticals (a Daiichi Sankyo U.S. subsidiary), that American Regent and PharmaForce merged into Luitpold, and that the surviving entity was renamed American Regent, Inc. effective January 2019. C8 – ownership chain for the US marketer of ProvayBlue: Daiichi Sankyo Company, Limited -> Luitpold Pharmaceuticals, Inc. (Shirley, New York) -> American Regent, Inc. The release states American Regent products provided 'more than 95% of Luitpold's revenue' and lists Injectafer and Venofer among them; all three merging entities were wholly owned by Daiichi Sankyo, paid-in capital Luitpold US$200,000. It does not mention methylene blue or ProvayBlue – the ProvayBlue link is established by the label (manufacturer American Regent, Inc.) and NDA 204630 (holder Provepharm SAS), not by this release. A later Daiichi Sankyo item (americanregent.com press release 'HBT Labs, Inc. to Join American Regent, Inc.' seen in search) was not opened. Study type: news.
